Information Provided By:
Fly News Breaks for March 13, 2018
REGN
Mar 13, 2018 | 06:34 EDT
Deutsche Bank analyst Navin Jacob lowered his price target for Regeneron Pharmaceuticals to $367 saying that while near term concerns on Dupixent are misplaced, he's concerned that Dupixent consensus estimates are too high over the mid and long term. The analyst keeps a Hold rating on Regeneron.
News For REGN From the Last 2 Days
There are no results for your query REGN